

Nuformix plc

Appointment of Madeleine Kennedy as Non-Executive Director

Cambridge, UK – 2 December 2020: Nuformix plc (LSE:NFX; “Nuformix”, the “Company” or the “Group”), a drug re-purposing specialist, is pleased to announce that Madeleine “Maddy” Kennedy, FCCA, will join the Board of Nuformix as a Non-Executive Director with immediate effect. Maddy will be appointed as Chair of the Audit Committee.

Maddy is currently CFO and Board Director of Concepta PLC and CFO of CFO4Growth Limited. She has previously acted as interim CFO for Ieso Digital Health Ltd and PsiOxus Therapeutics Ltd, was CFO for Lab21 Limited and Finance Director at Alliance Pharma plc, taking it through its IPO. She specialises in growing life science businesses and has more than 20 years' experience in the sector, both in public and private companies.

Dr Chris Blackwell, Executive Chairman, commented:

“It’s a pleasure for us to welcome Maddy to the Board. Maddy’s knowledge and experience will be extremely valuable as the Company moves forward with its near-term strategic priorities.”

Commenting on her appointment, Maddy Kennedy said:

“I am delighted to be joining the Board of Nuformix and look forward to working with the Board and the team, to achieve its strategic objectives.”

No further information is required to be disclosed pursuant to LR 9.6.13R of the UK Listing Rules.

The person responsible for arranging the release of this announcement on behalf of the Company is Dr Chris Blackwell, Executive Chairman.

Enquiries:

Nuformix plc

Dr Chris Blackwell, Executive Chairman

+44 (0)1223 627222

Fleur Wood, Investor Relations

Email: fleur.wood@nuformix.com

Novum Securities Limited

+44 (0)20 7399 9427

Jon Belliss / Colin Rowbury

About Nuformix

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form. Nuformix’s model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide

range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information please visit www.nuformix.com.